New: Introducing the Finviz Futures Map

Praxis Precision Medicines, Inc.

Contributing Author

Recent Articles by Praxis Precision Medicines, Inc.

Aug-29	Praxis Precision Medicines to Participate in Upcoming Fireside Chat PRAX GlobeNewswire
Aug-25	Praxis Medicines to Present at 36th International Epilepsy Congress 2025 in Lisbon, Showcasing Latest RADIANT Study Data and Leading Precision Epilepsy Pipeline PRAX GlobeNewswire
Aug-06	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PRAX GlobeNewswire
Aug-05	Praxis Precision Medicines to Participate in Upcoming Fireside Chat PRAX GlobeNewswire
Aug-04	Praxis Precision Medicines to Participate in Upcoming Fireside Chat PRAX GlobeNewswire
Aug-04	Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results PRAX GlobeNewswire
Aug-04	Praxis Precision Medicines Announces Positive, Best-in-Disease Topline Results in Patients with Focal Onset Seizures from the RADIANT Study of Vormatrigine PRAX GlobeNewswire
Jul-29	Praxis Precision Medicines to Host Conference Call to Announce Topline Results from the RADIANT Trial and Provide Second Quarter 2025 Financial Results PRAX GlobeNewswire
Jul-17	Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies PRAX GlobeNewswire
Jul-02	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PRAX GlobeNewswire
Jun-04	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PRAX GlobeNewswire
May-20	Praxis Precision Medicines to Participate in Upcoming Conferences PRAX GlobeNewswire
May-05	Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event PRAX GlobeNewswire
May-02	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PRAX GlobeNewswire
May-02	Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results PRAX GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.